Psychedelic stocks are well off of their 2020 highs. But they are even further from their 2020 lows. Opportunity knocks.
Mind Cure Health Inc
Company:
Mind Cure Health Inc
Symbol:
MCUR
Country:
Canada
Sector:
Life Sciences
Industry:
psychedelic drugs
Established:
2020
Website:
Company:
Mind Cure Health Inc
Symbol:
MCUR
Country:
Canada
Sector:
Life Sciences
Industry:
psychedelic drugs
Established:
2020
Website:
Company Brief
Mind Cure Health Inc (CAN:MCUR / US:MCURF) is a life sciences company focusing on opportunities in psychedelic drug development and mental health services. Mind Cure’s quest is to treat the profound distress of a world suffering from a Mental Health Crisis.
Mind Cure’s founding team and advisors have deep industry-specific experience in biotech, life sciences, new product discovery, research, technology, and entrepreneurship. The company is uniquely situated in Canada, benefiting from a sophisticated investment community, world-class scientific professionals, and government leadership in research.
Mind Cure’s founding team and advisors have deep industry-specific experience in biotech, life sciences, new product discovery, research, technology, and entrepreneurship. The company is uniquely situated in Canada, benefiting from a sophisticated investment community, world-class scientific professionals, and government leadership in research.
52-Week Range:
CAD$0.20 - $1.09
Current Outstanding:
53,422,596
Warrants:
9,139,404
Options:
7.205,000
Fully Diluted:
69,767,000
Market Cap:
CAD$48.6 million
52-Week Range:
CAD$0.20 - $1.09
Current Outstanding:
53,422,596
Warrants:
9,139,404
Options:
7.205,000
Fully Diluted:
69,767,000
Market Cap:
CAD$48.6 million
Highlights
- Led by Kelsey Ramsden, twice Canada’s Top Female Entrepreneur, and the first female CEO of a public psychedelic drug company
- A wealth of psychedelic drug expertise/experience among MCUR’s team of Advisors, including Hamilton Morris and Dr. Dan Engle
- Will be opening first psychedelic-assisted mental health therapy clinic in May 2021, offering both ketamine- and psilocybin-assisted therapy
- Recent acquisition of a digital therapeutics platform will enhance and streamline clinic operations
- Initial focus of psychedelic drug R&D is on ketamine-, psilocybin- and ibogaine-derived compounds
Related Articles
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
MINDCURE's new Director is a veteran of capital markets.
TSI EDITOR |
2021-02-22
MINDCURE’s Psychedelics R&D Targets Blockbuster TBI Treatment Market
MINDCURE's R&D on traumatic brain injury (TBI) targets the LARGEST individual market for psychedelic drugs.
TSI EDITOR |
2021-02-19
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
MINDCURE's first line of mushroom-based nootropics now available for sale.
TSI EDITOR |
2021-02-18
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
TSI EDITOR |
2021-02-17
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
MINDCURE adds bioinformatics to its drug development platform.
TSI EDITOR |
2021-02-16
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now